<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="167216">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920699</url>
  </required_header>
  <id_info>
    <org_study_id>PREQUEL-01.00</org_study_id>
    <secondary_id>NIH grant: 1 R01 NS060118-01A1</secondary_id>
    <nct_id>NCT00920699</nct_id>
  </id_info>
  <brief_title>Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)</brief_title>
  <acronym>PREQUEL</acronym>
  <official_title>A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huntington Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Huntington Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the tolerability of treatment with 600, 1200 or 2400 mg per day of coenzyme Q10
      in pre-manifest participants carrying the CAGn expansion for Huntington's Disease (HD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      secondary objectives:

        1. To assess the change from baseline to 20 weeks on biomarkers of oxidative stress (8OHdG
           and 8OHrG) and DNA repair mechanisms (OGG1) in pre-manifest participants treated with
           600, 1200 or 2400 mg per day of CoQ10.

        2. To assess the dose-response relationship between CoQ10 at dosages of 600, 1200 or 2400
           mg per day and 8OHdG/8OHrG and OGG1.

        3. To assess the serum levels of CoQ10 at 600, 1200 or 2400 mg in pre-manifest
           participants and their relationship to 8OHdG/8OHrG and OGG1.

        4. To assess the feasibility of implementing a preventive therapeutic trial in a
           pre-manifest population.

        5. To assess the utility and stability of clinical measures of HD, social relations,
           behavior and employment in a pre-manifest sample enrolled in a treatment trial.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability: Ability to complete the study on the originally randomized treatment assignment.</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional Tolerability</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (labs and clinical)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (8OHdG/8OHrG and OGG1)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CoQ10 Levels</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical (UHDRS '99;FASRBE;IADL;BDI-II;C-SSRS)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility (Enrollment rate;completing the study;visit and study med compliance)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>600 mg per day of CoQ10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will start on a dosage of 600 mg/day of CoQ10 in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1200 mg per day of CoQ10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2400 mg per day of CoQ10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CoQ10</intervention_name>
    <description>Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.</description>
    <arm_group_label>600 mg per day of CoQ10</arm_group_label>
    <arm_group_label>1200 mg per day of CoQ10</arm_group_label>
    <arm_group_label>2400 mg per day of CoQ10</arm_group_label>
    <other_name>-Ubiquinone</other_name>
    <other_name>-coenzyme Q10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will be positive for the CAGn expansion in the Huntingtin gene (&gt;36
             repeats) and be pre-manifest by virtue of scoring 3 or less on diagnostic confidence
             level (Question 17 of the UHDRS)

          -  Participants will have received genetic testing prior to enrollment through a
             standard pre-manifest testing protocol.

          -  18 years of age or older.

          -  Concomitant medications are permitted with the exception of CoQ10, creatine &gt; 5g/day
             and warfarin.

        Exclusion Criteria:

          -  History of intolerability to CoQ10.

          -  CoQ10 use within 60 days prior to randomization.

          -  Unstable medical or psychiatric illness;

          -  Substance abuse within one year of the baseline visit.

          -  Pregnancy, breastfeeding or lack of reliable contraception in women of childbearing
             age.

          -  Subjects with known allergy to FD&amp;C #6 yellow food coloring.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher A Ross, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin M Biglan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hereditary Neurological Disease Centre (HNDC)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.huntington-study-group.org</url>
    <description>Huntington Study Group</description>
  </link>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 28, 2012</lastchanged_date>
  <firstreceived_date>June 9, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Christopher A. Ross, MD, PhD-Principal Investigator</name_title>
    <organization>Johns Hopkins University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
